Tag Archives: Andrew D’silva

ClearPoint Neuro (CLPT) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Andrew D’silva maintained a Buy rating on ClearPoint Neuro (CLPT – Research Report) yesterday and set a price target of $8.00. The company’s shares closed last Thursday at $3.91. According to TipRanks.com, D’silva is a 4-star analyst

Eton Pharmaceuticals (ETON) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Andrew D’silva reiterated a Buy rating on Eton Pharmaceuticals (ETON – Research Report) today and set a price target of $12.00. The company’s shares closed last Wednesday at $6.38. According to TipRanks.com, D’silva is a 4-star analyst

Harrow Health (HROW) Gets a Buy Rating from B.Riley FBR

In a report released yesterday, Andrew D’silva from B.Riley FBR maintained a Buy rating on Harrow Health (HROW – Research Report), with a price target of $11.50. The company’s shares closed last Tuesday at $6.15. According to TipRanks.com, D’silva is

B.Riley FBR Sticks to Their Hold Rating for EyePoint Pharmaceuticals (EYPT)

In a report released today, Andrew D’silva from B.Riley FBR reiterated a Hold rating on EyePoint Pharmaceuticals (EYPT – Research Report), with a price target of $0.80. The company’s shares closed last Tuesday at $0.66, close to its 52-week low

Analysts Are Bullish on These Healthcare Stocks: Intricon (IIN), ProQR (PRQR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intricon (IIN – Research Report) and ProQR (PRQR – Research Report) with bullish sentiments. Intricon (IIN) In a report released today, Andrew

B.Riley FBR Believes CryoPort (NASDAQ: CYRX) Still Has Room to Grow

In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on CryoPort (CYRX – Research Report), with a price target of $40.00. The company’s shares closed last Thursday at $34.98, close to its 52-week high of